Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population
Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population
复制标题
DOI：
10.1016/s0140-6736(03)14307-3
复制
发表时间：
2003-09-13
期刊：
影响因子：
168.9
通讯作者：
Hirschel, B
中科院分区：
文献类型：
--
作者：
Jaggy, C;von Overbeck, J;Hirschel, B
由于过去死亡率较高，HIV-1患者无法获得人寿保险。我们在1997年至2001年的瑞士艾滋病毒队列研究(SHCS)中测量了死亡率，并将其与瑞士参考人群的死亡率进行了比较。在成功接受高效抗逆转录病毒治疗(HAART)且未同时感染丙型肝炎病毒的患者中，每年的额外死亡率低于千分之五。治疗成功的癌症患者的额外死亡率大致相同，但并未被排除在人寿保险保单之外。
Because of high death rates in the past, patients with HIV-1 cannot obtain life insurance. We measured mortality rates in the Swiss HIV Cohort Study (SHCS) from 1997 to 2001 and compared them with those of the Swiss reference population. In patients who were successfully treated with highly active anti-retroviral therapy (HAART), and who were not also infected with the hepatitis C virus, excess death rates were below five per thousand per year. Patients with successfully treated cancer have much the same excess death rates but are not excluded from life insurance policies.